Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) ("
Innate" or the "
Company")
today announced the launch of HopeConnectLearn, a new online
resource for the hairy cell leukemia community. HopeConnectLearn
provides education and connection for patients and their caregivers
across the spectrum of disease, from a new diagnosis to relapse or
refractory experiences.
HopeConnectLearn includes a website and social
media channels where patients and caregivers can find information
about this rare disease and tools to help empower patients in
conversations with their physician, as well as patient stories.
"A hairy cell leukemia diagnosis or relapse or
refractory experience can be daunting for patients, and connection
with others navigating similar challenges can provide needed
comfort and strength," said Jennifer Butler, Executive Vice
President and General Manager, Innate Pharma US,
Inc. "HopeConnectLearn provides a
community for patients to connect with and learn from each others’
experience, no matter where they are in their journey."
Hairy cell leukemia is a rare blood cancer
accounting for two to three percent of all cases of adult leukemias
in the U.S., with approximately 1,000 new cases diagnosed each
year.i_ii The disease affects more men than women, and occurs
most commonly in middle-aged or older adults. Its name stems from
the thin, hair-like projections found on the surface of abnormal
white blood cells that indicate the disease.
This is often a slow growing, or indolent, form
of cancer, and 90 percent of patients will have a normal life
expectancy. About 40 percent of patients will relapse in 5-10 years
following first treatment.iii_iv
"When facing a rare disease like hairy cell
leukemia, patients derive hope from hearing directly from other
patients and learning about their experiences," said Anna
Lambertson, Executive Director of the Hairy Cell Leukemia
Foundation. "It is important for patients and caregivers
across the spectrum of disease to know that they are not
alone."
Join the HopeConnectLearn community online at
www.hopeconnectlearn.com, on Twitter @HopeConnectLrn, Instagram
@HopeConnectLearn and at www.Facebook.com/HopeConnectLearn.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate Pharma has been a pioneer in the
understanding of natural killer cell biology and has expanded its
expertise in the tumor microenvironment and tumor-antigens, as well
as antibody engineering. This innovative approach has resulted in a
diversified proprietary portfolio and major alliances with leaders
in the biopharmaceutical industry including Bristol-Myers Squibb,
Novo Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
For additional
information, please contact:
InvestorsInnate
Pharma
Tel.: +33 (0)4 30 30 30 30investors@innate-pharma.com |
MediaInnate Pharma Tracy Rossin
(Global/US)Tel.: +1 240 801 0076Tracy.Rossin@innate-pharma.com |
Disclaimer on
forward-looking information and risk
factors:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an
additional discussion of risks and uncertainties which could cause
the company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
_________________________
i Lopez-Rubio M, Garcia-Marco JA. Current
and emerging treatment options for hairy cell leukemia. Onco
Targets Ther. 2015;8:21247-2156.ii Troussard X, Cornet E.
Hairy cell leukemia 2018: update on diagnosis, risk-stratification,
and treatment. Am J Hematol. 2017; 92(12): 1382-1390.iii Teras
LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US
lymphoid malignancy statistics by World Health Organization
subtypes. CA Cancer J Clin. 2016;66(6):443-459.
doi:10.3322/caac.21357.iv Grever MR, Blachly JS, Andritsos LA.
Hairy cell leukemia: Update on molecular profiling and therapeutic
advances. Blood Rev. 2014;28(5):197-203.
doi:10.1016/j.blre.2014.06.003.
Innate Pharma (EU:IPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Sep 2023 to Sep 2024